Study of Everolimus in the Treatment of Advanced Malignancies in Patients With Peutz-Jeghers Syndrome
Status:
Withdrawn
Trial end date:
2015-04-01
Target enrollment:
Participant gender:
Summary
In this pilot study the investigators will treat all patients known with Peutz-Jeghers
syndrome (PJS) who are diagnosed with advanced malignancies with everolimus 10mg daily until
disease progression. Most patients with PJS have an inherited LKB1 mutation leading to
aberrant m-TOR activity. Their risk to develop malignancies or intestinal polyps is probably
related to this constitutive mTOR signaling. The hypothesis is that mTOR inhibition is an
effective anticancer treatment in PJS patients with advanced malignancies.
Phase:
Phase 2
Details
Lead Sponsor:
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)